OncoGenex - Articles and news items

OncoGenex’s Phase 3 non-small cell lung cancer trial did not meet primary endpoint

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

OncoGenex’ results, analysed from the Phase 3 trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+